All In MedTech

FDA Clearance Tracker · P940035-S002

MATRITECH NMP22 TEST KIT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 18, 2000 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 18, 2000

Approved

Time to decision

179 days

Received Jul 23, 1999. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P940035-S002
Device name
MATRITECH NMP22 TEST KIT
Applicant location
Scarborough, ME
Received
Jul 23, 1999
Decided
Jan 18, 2000
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P940035

Device type

Device class
Class III

Every decision under product code NAH

FDA's approval statement

As written in FDA's record.

The device is used as an aid 1)in the diagnosis of persons with symptoms or risk factors for transitional cell cancer (TCC) of the bladder (cut-off >= 7.5U/ml) in conjunction with and not in lieu of current standard diagnostic procedures and 2) in the management of patients with transitional cell carcinoma of the bladder, after surgical treatment to identify those patients with occult or rapidly recurring TCC (cut-off >10U/ml).

Source documents

Other decisions for Abbott Diagnostics Scarborough, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

6 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.